Youning Liu
Overview
Explore the profile of Youning Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1049
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Identification and characterization of the capsule depolymerase Dpo27 from phage IME-Ap7 specific to
Wang R, Liu Y, Zhang Y, Yu S, Zhuo H, Huang Y, et al.
Front Cell Infect Microbiol
. 2024 May;
14:1373052.
PMID: 38808067
Among the genus, stands out as an important opportunistic infection causative agent commonly found in hospital settings, which poses a serious threat to human health. Recently, the high prevalence of...
2.
Zhang J, Cheng Q, Huang Y, Fan H, Lai G, Mu X, et al.
Chin Med J (Engl)
. 2022 Dec;
135(22):2653-2655.
PMID: 36574216
No abstract available.
3.
Ni W, Yang D, Guan J, Xi W, Zhou D, Zhao L, et al.
J Antimicrob Chemother
. 2021 Apr;
76(8):2097-2105.
PMID: 33860309
Objectives: Carbapenem-resistant Klebsiella pneumoniae (CR-KP) infections represent severe threats to public health worldwide. The aim of this study was to assess potential synergistic interaction between tigecycline and aminoglycosides via in...
4.
He N, Su S, Ye Z, Du G, He B, Li D, et al.
Clin Infect Dis
. 2020 Dec;
71(Suppl 4):S363-S371.
PMID: 33367582
Background: Clinical practice guidelines or recommendations often require timely and regular updating as new evidence emerges, because this can alter the risk-benefit trade-off. The scientific process of developing and updating...
5.
Zhao J, Liu Y, Liu Y, Wang D, Ni W, Wang R, et al.
Front Microbiol
. 2018 Apr;
9:549.
PMID: 29632524
is an emerging nosocomial pathogen with high resistance to most clinically used antimicrobials. Tigecycline is a potential alternative antimicrobial for infection treatment, but its resistance mechanism in clinical isolates is...
6.
Ni W, Li G, Zhao J, Cui J, Wang R, Gao Z, et al.
Infect Dis (Lond)
. 2018 Jan;
50(7):507-513.
PMID: 29316830
Background: Pneumonia caused by carbapenemase-producing Klebsiella pneumoniae (CP-KP) are increasingly encountered in hospitals worldwide, causing high mortality due to lack of treatment options. The goal of this study was to...
7.
Ni W, Yang D, Mei H, Zhao J, Liang B, Bai N, et al.
Antimicrob Agents Chemother
. 2017 Jan;
61(4).
PMID: 28115351
We determined the concentration-time profiles of ciprofloxacin and amikacin in serum and alveolar epithelial lining fluid (ELF) of rats with or without pulmonary fibrosis and investigated the effect of pulmonary...
8.
Ni W, Han Y, Zhao J, Cui J, Wang K, Wang R, et al.
Sci Rep
. 2016 Dec;
6:39481.
PMID: 27991579
The serum concentration of soluble urokinase-type plasminogen activator receptor (suPAR) reflects immune activation. We performed a meta-analysis to evaluate the usefulness of suPAR for the diagnosis and prognosis of bacterial...
9.
Zhao J, Xing Y, Liu W, Ni W, Wei C, Wang R, et al.
Front Microbiol
. 2016 Nov;
7:1723.
PMID: 27833606
is a common nosocomial pathogen that causes high morbidity and mortality. Because of its inherent extended antibiotic resistance, therapeutic options for are limited, and sulfamethoxazole/trimethoprim (SXT) is the only first-line...
10.
Zhao T, Chen L, Wang P, Tian G, Ye F, Zhu H, et al.
J Thorac Dis
. 2016 Oct;
8(9):2473-2484.
PMID: 27746999
Background: To compare 5-day regimen of levofloxacin 750 mg IV daily with 7-14-day conventional regimen of levofloxacin 500 mg intravenous to oral (IV/PO) daily for treatment of community-acquired pneumonia (CAP)...